JPH0376561A - Digestion-resistant useful enterobacterium and its preparation - Google Patents
Digestion-resistant useful enterobacterium and its preparationInfo
- Publication number
- JPH0376561A JPH0376561A JP1210102A JP21010289A JPH0376561A JP H0376561 A JPH0376561 A JP H0376561A JP 1210102 A JP1210102 A JP 1210102A JP 21010289 A JP21010289 A JP 21010289A JP H0376561 A JPH0376561 A JP H0376561A
- Authority
- JP
- Japan
- Prior art keywords
- capsule
- bacteria
- edible
- useful
- digestion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000029087 digestion Effects 0.000 title claims abstract description 6
- 239000002775 capsule Substances 0.000 claims abstract description 49
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 29
- 241000894006 Bacteria Species 0.000 claims abstract description 25
- 210000000813 small intestine Anatomy 0.000 claims abstract description 13
- 238000002844 melting Methods 0.000 claims abstract description 7
- 230000008018 melting Effects 0.000 claims abstract description 7
- 239000011248 coating agent Substances 0.000 claims abstract description 5
- 238000000576 coating method Methods 0.000 claims abstract description 5
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 4
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 4
- 229920000642 polymer Polymers 0.000 claims abstract 2
- 230000000968 intestinal effect Effects 0.000 claims description 13
- 210000000936 intestine Anatomy 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 12
- 239000008157 edible vegetable oil Substances 0.000 claims description 6
- 230000009286 beneficial effect Effects 0.000 claims description 4
- 230000001079 digestive effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000010419 fine particle Substances 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 abstract description 16
- 210000004051 gastric juice Anatomy 0.000 abstract description 7
- 241000305071 Enterobacterales Species 0.000 abstract 5
- 230000000415 inactivating effect Effects 0.000 abstract 1
- 239000003925 fat Substances 0.000 description 16
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 239000003921 oil Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 150000004804 polysaccharides Chemical class 0.000 description 5
- 239000004367 Lipase Substances 0.000 description 4
- 102000004882 Lipase Human genes 0.000 description 4
- 108090001060 Lipase Proteins 0.000 description 4
- 229940040461 lipase Drugs 0.000 description 4
- 235000019421 lipase Nutrition 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 239000000783 alginic acid Chemical class 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Chemical class 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004534 cecum Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 229920002581 Glucomannan Polymers 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940046240 glucomannan Drugs 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical class [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 206010056325 Faecaloma Diseases 0.000 description 1
- 208000008415 Fecal Impaction Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、ビフィズス菌群のように大腸内において人体
に有用な作用を有する細菌を胃腸で失活させるこよなく
大腸に到達させる耐消化性腸内有用細菌及びその製法に
関する。Detailed Description of the Invention [Field of Industrial Application] The present invention provides a digestive resistant intestine that allows bacteria, such as Bifidobacteria, that have a beneficial effect on the human body in the large intestine to be inactivated in the gastrointestinal tract and to reach the large intestine. Concerning internally useful bacteria and their production method.
腸内有用細菌であるビフィズス菌群は嫌気性菌であり、
酸素、酸及び湿度に弱い。人種、環境、年齢等によりビ
フィズス菌群の量は異なるが、空腸、回腸、盲腸、直腸
に存在し、特に大腸部位に多く存在することが判明して
いる。大量のビフィズス菌群が大腸に存在すると、大腸
内の細菌相が理想的に保たれ、病原菌の腸向惑染を予防
し、下痢を予防及び治療し、宿便が解消し、成人病を予
防し、免疫力を高めるなどの効果があり、一般に個体の
加齢に伴いビフィズス菌の量が減少する傾向がある。（
光岡知足、製薬工場、ＶＯＬ。６． Ｎｏ、５（１９８
６）、 Ｐ、４２４〜４８８）このようなビフィズス菌
群を大腸内に大量に繁殖させる次（、経口的に食品と共
に外部から供給する方法は種々検討されている。しかし
ながら、従来の方法はすべてビフィズス菌を液状、ペー
スト状、粉状、顆粒状、錠剤などの形態で投４してきた
ため、胃内部を通過する際、胃粘膜より産生される強酸
性の胃液により失活し、腸内到達以前にビフィズス菌は
その効力を失っていた。The Bifidobacteria group, which is a useful intestinal bacteria, is an anaerobic bacteria.
Sensitive to oxygen, acids and humidity. Although the amount of Bifidobacteria group varies depending on race, environment, age, etc., it has been found that they are present in the jejunum, ileum, cecum, and rectum, and are particularly abundant in the large intestine. When a large amount of Bifidobacteria exists in the large intestine, the bacterial flora in the large intestine is ideally maintained, preventing pathogens from spreading to the intestine, preventing and treating diarrhea, eliminating fecal impaction, and preventing adult diseases. , has effects such as increasing immunity, and the amount of Bifidobacterium generally tends to decrease as an individual ages. (
Tomozoku Mitsuoka, Pharmaceutical Factory, VOL. 6. No. 5 (198
6), P, 424-488) Various methods have been studied to propagate large numbers of such Bifidobacterium groups in the large intestine and supply them orally along with food. However, all conventional methods Bifidobacterium has been administered in the form of liquid, paste, powder, granules, tablets, etc., so when it passes through the stomach, it is inactivated by the strongly acidic gastric juices produced by the gastric mucosa, and before it reaches the intestines. Bifidobacterium had lost its potency.
〔発明が解決しようとする課題〕
経口的に投与きれたビフィズス菌群が胃内を通過する際
に、失活されないようにビフィズス菌を保護し、腸内特
に大腸に到達させ、大腸で大量のビフィズス菌が放出き
れる技術が求められていた。[Problem to be solved by the invention] When the orally administered Bifidobacterium group passes through the stomach, it protects the Bifidobacterium from being deactivated, allows it to reach the intestine, especially the large intestine, and collects a large amount in the large intestine. There was a need for a technology that could release bifidobacteria.
本発明は上記課題を解決するものであって、その構成は
、腸内有用細菌が、可食性フィルムからなるカプセル内
に収納され、このカプセルが融点３５℃以正の食用油脂
で被覆きれていることを特徴とし、更に、可食性フィル
ムが非消化性であり、細菌が通過できる大きさの複数の
微細孔を穿設したことを特徴とする。或いは、可食性フ
ィルムが非消化性であり、小腸内において消化され、消
化後、細菌が通過できる大きさの微細孔を形成する微粒
子が配合されていることを特徴とする。 本発明におけ
る腸内有用細菌とは、ビフィズス菌に限定されるもので
はなく、乳酸菌、連鎖状球菌属であるフェカリス、乳酸
杆菌属であるアシドフィルス等腸内細菌相を良好に保つ
ものは全て包含される。中でもビフィズス菌属で代表さ
れるロンガムが好ましい。The present invention solves the above problems, and has a structure in which beneficial intestinal bacteria are housed in a capsule made of an edible film, and the capsule is completely covered with an edible oil or fat having a melting point of 35°C or higher. It is further characterized in that the edible film is non-digestible and has a plurality of micropores large enough to allow bacteria to pass through. Alternatively, the edible film is non-digestible, is digested in the small intestine, and contains microparticles that form micropores large enough to allow bacteria to pass through after digestion. In the present invention, the beneficial bacteria in the intestines are not limited to Bifidobacteria, but include all those that maintain a good intestinal flora, such as lactic acid bacteria, Streptococcus faecalis, and Lactobacillus acidophilus. Ru. Among them, longum typified by the genus Bifidobacterium is preferred.
腸内有用細菌はカプセルに収納する。カプセルは更にそ
の表面が食用油脂で被覆されているため、胃内における
消化のおそれはないが、胃内で破袋しないだけの剛性或
いは強度を有する可食性物質である。中でも、小腸内に
おいても消化されない非消化性の素材が好ましい。Useful intestinal bacteria are stored in capsules. Since the surface of the capsule is further coated with edible fat, there is no risk of ingestion in the stomach, but it is an edible substance that has enough rigidity or strength to not break in the stomach. Among these, non-digestible materials that are not digested even in the small intestine are preferred.
例えば、特開昭６３−２８３８０号や、特開昭６３−１
６４８５８号に開示された多価アルコール、糖アルコー
ル、単糖類、三糖類及びオリゴ糖から選ばれた少なくと
も１種の濃厚溶液の中で、カラギナン、アルギン酸、ア
ルギン酸誘導体、寒天、ローカストビーンガム、グアー
ガム、タマリンド種子多糖類、ペクチン、キサンタンガ
ム、グルコマンナン、キチン質、プルランから選ばれた
少な（とも１種の天然多糖類をアルカリの存在下または
非存在下に均一に混練して得られた天然多糖類・多価ア
ルコールＡｌｌ酸物が好ましい。しかしこれに限定され
るものではなくコラーゲン等の蛋白質も使用できる。For example, JP-A-63-28380, JP-A-63-1
Carrageenan, alginic acid, alginic acid derivatives, agar, locust bean gum, guar gum, A natural polysaccharide obtained by homogeneously kneading a few natural polysaccharides selected from tamarind seed polysaccharide, pectin, xanthan gum, glucomannan, chitin, and pullulan in the presence or absence of alkali. - Polyhydric alcohol All-acid is preferred.However, it is not limited to this, and proteins such as collagen can also be used.
カプセルの製法としては、例えば、上記素材の′ａ、厚
水溶水溶液プセルの型を浸漬し、乾燥させてもよ（、前
もって製造したシートを加熱圧縮して一定の型に成形し
てもよい。Capsules can be manufactured by, for example, immersing a capsule mold in a thick aqueous solution of the above-mentioned material and drying it (or heating and compressing a previously manufactured sheet to form it into a certain mold).
カプセルには複数の微細な孔を穿設する。孔の大赤さは
素材の種類、厚さによっても異なるが、細菌が自由に通
過できる大きさであり、０．１〜５μ好ましくは０．５
〜３μである。孔を設けるにあたっては、カプセルの型
内に複数の針状物を自由に突出させたり、収納したりで
きる装置を設はカプセル底形の際は突出させ、脱型の際
は収納させればカプセル成形と同時に複数の孔を設ける
ことができる。或いはカプセル成形後に孔を設けてもよ
（、熱針による機械的方法、レーザービーム等による方
法もある。更に、消化性素材の粒子を非消化性のカプセ
ル素材に混合してカプセルを成形してもよい、この場合
は孔を有しないカプセルであるが、小腸内において消化
性素材が消化消滅し、その後に複数の孔が穿設される。Multiple fine holes are made in the capsule. The large redness of the pores varies depending on the type and thickness of the material, but it is a size that allows bacteria to freely pass through, and is 0.1 to 5μ, preferably 0.5μ.
~3μ. To create the holes, a device that can freely protrude and store multiple needle-like objects inside the capsule mold is installed. A plurality of holes can be formed at the same time as molding. Alternatively, holes may be formed after forming the capsule (mechanical methods using hot needles, laser beams, etc.) are also available.Furthermore, particles of digestible material may be mixed with non-digestible capsule material and capsules may be formed. In this case, the capsule does not have holes, but the digestible material is digested and disappears in the small intestine, and then multiple holes are made.
この場合には、消化性素材の粒子は少なくとも細菌が自
由に通過できる大きさであることを要する。In this case, the particles of digestible material must be at least large enough to allow free passage of bacteria.
更に胃内通過中にカプセル中に胃液が浸透するのを防ぐ
ために、カプセル外表面に食用油脂を緻密に被覆する。Furthermore, in order to prevent gastric juices from penetrating into the capsule during passage through the stomach, the outer surface of the capsule is densely coated with edible oil or fat.
食用油脂は胃内温度により脱落しない溶融温度を要し、
３５度以上、好ましくは、４５〜６０’Ｃである。現実
には食用硬化油脂、牛脂、豚脂などが好ましく使用され
る。Edible fats and oils require a melting temperature that does not fall off depending on the temperature in the stomach.
The temperature is 35 degrees or higher, preferably 45 to 60'C. In reality, edible hydrogenated fats and oils, beef tallow, pork fat, etc. are preferably used.
このようにしてカプセルは胃液の直接接触から保・護さ
れて腸内に到達する。！ｉ内において油脂は胃リパーゼ
、腸リパーゼ、膵リパーゼ、胆汁などの作用により消化
され、カプセルが露出する。カプセルが蛋白質、消化性
多糖類などの消化性素材であれば小腸内でビフィズス菌
はすべて放出される。小腸は消化作用が強く、ビフィズ
ス菌にとって好環境ではないため、小腸内での放出を最
小に止め、大腸まで到達させることが好ましい。非消化
性のカプセル素材を用い複数の孔を穿設した場合には小
腸から大腸にいたる間連続的にビフィズス菌を放出し続
けるため、大腸に多数のビフィズス菌を到達させること
ができる。In this way the capsule reaches the intestine protected and protected from direct contact with gastric juices. ! Inside the capsule, fats and oils are digested by the action of gastric lipase, intestinal lipase, pancreatic lipase, bile, etc., and the capsule is exposed. If the capsule is made of digestible material such as protein or digestible polysaccharide, all bifidobacteria will be released in the small intestine. Since the small intestine has a strong digestive action and is not a favorable environment for bifidobacteria, it is preferable to minimize release in the small intestine and allow it to reach the large intestine. When a non-digestible capsule material is used and multiple holes are made, bifidobacteria are continuously released from the small intestine to the large intestine, allowing a large number of bifidobacteria to reach the large intestine.
大腸内に到達したビフィズス菌が更に増殖するために、
食用油脂で被覆したカプセルをビフィズス菌の増殖促進
要素であるフラクトオリゴ糖を主成分とする調味物質で
被覆することが好ましい。Bifidobacterium that has reached the large intestine further proliferates,
It is preferable that the capsule coated with edible oil or fat is coated with a seasoning substance whose main component is fructooligosaccharide, which is an element that promotes the growth of bifidobacteria.
フラクトオリゴ糖はシェークロース１分子にフラクトー
ス１〜４分子が結合した構造であり、低カロリー甘味料
としても使用される。Fructooligosaccharide has a structure in which one to four molecules of fructose are bound to one molecule of shake sugar, and is also used as a low-calorie sweetener.
［作用〕
本発明は、ビフィズス菌群を可食性のカプセルに収納し
、これを胃酸から保護するために胃内温度で溶解しない
可食性油脂で被覆したものである。[Function] In the present invention, bifidobacteria are housed in an edible capsule, and the capsule is coated with an edible fat that does not dissolve at the temperature of the stomach in order to protect it from gastric acid.
小腸に到達後は油脂は消化され、また、カプセルも消化
きれる。この際、好ましくはカプセル素材を非消化性と
し、カプセルに細菌が通過できる複数の孔を穿設すると
カプセルの形態が小腸に至っても崩壊しないため、ビフ
ィズス菌は孔から徐々に放出され、大腸まで到達し、更
に放出し続ける。After reaching the small intestine, fats and oils are digested, and capsules are also digested. At this time, preferably the capsule material is non-digestible and the capsule has multiple holes through which bacteria can pass, so that the capsule does not disintegrate even when it reaches the small intestine, so the bifidobacteria are gradually released from the holes and reach the large intestine. It reaches and continues to emit more.
そのため、経口的に大腸に大量のビフィズス菌を到達さ
せるこそが可能になり、腸内の細菌相を理想的に維持す
ることが可能になった。更に、食用油脂をフラクトオリ
ゴ糖で被覆すると摂取に際し口あたりがよいばかりでな
く、腸内到達後のビフィズス菌群増殖要素であり、ビフ
ィズス菌が一層活性化する。Therefore, it has become possible to orally deliver a large amount of bifidobacteria to the large intestine, making it possible to ideally maintain the bacterial flora in the intestine. Furthermore, when edible fats and oils are coated with fructooligosaccharides, they not only have a good taste when ingested, but also act as a growth factor for the bifidobacteria group after reaching the intestine, further activating the bifidobacteria.
以下の実施例におけるビフィズス菌の放出試験としては
、真島英信、生理学、文光堂版、４１８〜４４６頁を参
照したゆすなわち、試験経過時間として、背部３０分、
小腸（−二指腸から盲腸）４時間、大腸（盲腸から直腸
）１３時間３０分とした。実施例においては試験時間を
２部分に大別し、背部３０分、腸部１７時間３０分の合
計１８時間とした。For the release test of bifidobacteria in the following examples, reference was made to Hidenobu Mashima, Physiology, Bunkodo Edition, pages 418-446. In other words, the elapsed test time was 30 minutes on the back,
The time was 4 hours for the small intestine (from the duodenum to the cecum) and 13 hours and 30 minutes for the large intestine (from the cecum to the rectum). In the examples, the test time was roughly divided into two parts, 30 minutes for the back and 17 hours and 30 minutes for the intestines, for a total of 18 hours.
試験液は日本薬局方１０、一般試験法、７３４頁による
第１液（ｐＨ約１．２・・・・・・胃液相当）、第２液
（ｐＨ約６．８・・・・・・腸液相当）を用い、更に食
用油脂被膜を溶解する目的でリパーゼを添加した。The test solutions are the first solution (pH about 1.2...equivalent to gastric juice) and the second solution (pH about 6.8...intestinal fluid) according to Japanese Pharmacopoeia 10, General Test Methods, page 734. (equivalent) was used, and lipase was added for the purpose of dissolving the edible fat coating.
試験後、第２液中に放出されたビフィズス菌の確認には
、ＢＬ寒天培地に試験終了後の試験液を一定量散布し、
嫌気性培養を行い所定培養時間経過後コロニーの存在及
び個数を測定した。After the test, to confirm the bifidobacteria released in the second solution, spray a certain amount of the test solution after the test on the BL agar medium,
Anaerobic culture was performed, and after a predetermined culture time, the presence and number of colonies were measured.
１羞稠土
カラギナン６０重量部、アルギン酸２０重量部、ローカ
ストビーンガム１０重量部、グルコマンナン１０重量部
を混練し、これにグリセリン３０重量部を加えて良く混
合し、しめり気のある粉状の天然多糖類・多価アルコー
ル組成物を得た。1. Knead 60 parts by weight of homogeneous carrageenan, 20 parts by weight of alginic acid, 10 parts by weight of locust bean gum, and 10 parts by weight of glucomannan, add 30 parts by weight of glycerin and mix well to form a moist powder. A natural polysaccharide/polyhydric alcohol composition was obtained.
この組成物３重量部を９７重量部の水に溶解して粘稠な
溶液とし、この溶液を複数の針が遠隔操作で自由に突出
し、収納されるカプセル型を用いて平均膜厚５０〜（０
０μのカプセルを製造した。3 parts by weight of this composition is dissolved in 97 parts by weight of water to form a viscous solution, and this solution is prepared using a capsule type in which a plurality of needles are freely protruded and housed by remote control, with an average film thickness of 50 ~ ( 0
0μ capsules were manufactured.
このカプセルは耐熱性であり、孔の大きさは０．５〜３
μであった。このカプセルにビフィズス菌属のロンガム
（１０１個／ｇ）を０．５ｇ挿入し、カプセル末端を熱
融着して密封した。次いで、融点４０℃士２℃の食用硬
化油脂（ショートニング精製牛油、機関油脂工業■製）
を被覆した。This capsule is heat resistant and has a pore size of 0.5-3
It was μ. 0.5 g of Bifidobacterium longum (101 pieces/g) was inserted into this capsule, and the end of the capsule was sealed by heat-sealing. Next, edible hydrogenated fat with a melting point of 40°C to 2°C (shortening refined beef oil, manufactured by Kishin Yushi Kogyo ■)
coated.
このカプセルを第１液５００１１中、３７℃３０分間浸
漬し、次いで第２液２５０ｍ１に１７時間３０分浸漬し
た。第２液には市販のリパーゼ（天野製薬味製）０．１
ｇを添加した。浸漬終了後、浸漬液を種々の倍率に希釈
してＩｎ１１を採取し、ＢＬ寒天培地（栄研■製）に接
種後、３７℃１７２時間嫌気性培養を行い、コロニーの
数を測定した。なお、コロニーの数はシャーレ３枚の平
均個数である。This capsule was immersed in the first liquid 50011 at 37° C. for 30 minutes, and then in the second liquid 250 ml for 17 hours and 30 minutes. The second liquid contains 0.1 commercially available lipase (manufactured by Amano Pharmaceutical Flavor).
g was added. After the immersion was completed, the immersion solution was diluted to various ratios to collect In11, which was inoculated onto a BL agar medium (manufactured by Eiken ■), followed by anaerobic culture at 37° C. for 172 hours, and the number of colonies was measured. Note that the number of colonies is the average number of three Petri dishes.
１０．０００倍希釈で測定不能個数、１００．０００倍
希釈で８０個、ｉ、ｏｏｏ、ｏｏｏ倍希釈で５個のコロ
ニーが確認された。An unmeasurable number of colonies was confirmed at 10,000-fold dilution, 80 colonies at 100,000-fold dilution, and 5 colonies at i, ooo, and ooo-fold dilution.
実鳳樵ｉ
融点４０℃±５℃の食用硬化油脂（食用精製加工油脂、
横開油脂工業■製）を被覆した以外は実施例１と同様に
して試験を行った。その結果、ｉｏ、 ｏｏｏ倍希釈で
測定不能個数、ｉｏｏ、ｏｏｏ倍希釈で５０個、１，０
００，０００倍希釈で８個のコロニーが確認された。Edible hydrogenated fats and oils with a melting point of 40°C ± 5°C (edible refined processed fats and oils,
The test was conducted in the same manner as in Example 1, except that the sample was coated with Yokokai Yushi Kogyo (trade name)). As a result, the number of particles that could not be measured with io, ooo fold dilution, 50 pieces with ioo, ooo fold dilution, 1,0
Eight colonies were confirmed at 1:00,000 dilution.
止較拠土
カプセルを油脂を被覆しなかった点及び第２液にリパー
ゼを添加しなかった以外は実施例１と同様にして試験を
行った。その結果、１０倍希釈で測定不能個数、１００
倍希釈で５０個、１０００倍希釈で１２個、ｔｏ、ｏｏ
ｏ倍希釈で０個のコロニが確認された。The test was conducted in the same manner as in Example 1, except that the base capsules were not coated with oil and fat and lipase was not added to the second liquid. As a result, the number of unmeasurable particles after 10-fold dilution was 100.
50 pieces for 1-fold dilution, 12 pieces for 1000-fold dilution, to, oo
0 colonies were confirmed at o-fold dilution.
且教朋Ｊ−
従来の技術にしたがい、ビフィズス菌を被覆保護するこ
となく、そのまま実施例１の試験を行った場合には、胃
液により完全に失活し、コロニーは存在しなかった。When the test of Example 1 was conducted according to the conventional technique without coating and protecting the bifidobacteria, they were completely inactivated by gastric juice and no colonies were present.
本発明により、腸内有用細菌を胃液により失活されるこ
よなく腸内に到達させることが可能になり、腸内細菌相
を常に正常に保つことが容易になった。According to the present invention, it has become possible to allow useful intestinal bacteria to reach the intestines without being inactivated by gastric juice, and it has become easy to maintain the intestinal bacterial flora in a normal state at all times.
Claims (6)
該カプセルが融点３５℃以上の食用油脂で被覆されてい
る耐消化性腸内有用細菌。(1) Stored in a capsule made of edible film,
Digestible bacteria useful for the intestine, the capsule of which is coated with an edible oil or fat having a melting point of 35°C or higher.
り、細菌が通過できる大きさの複数の微細孔を穿設した
請求項第１項記載の耐消化性腸内有用細菌。(2) The digestive resistant intestinal useful bacteria according to claim 1, wherein the capsule made of an edible film is indigestible and has a plurality of micropores large enough to allow the bacteria to pass through.
て消化され、消化後、細菌が通過できる大きさの微細孔
を形成する微粒子が可食性フィルム素材に配合されてい
る請求項第１項記載の耐消化性腸内有用細菌。(3) The edible film material is non-digestible, and the edible film material contains fine particles that are digested in the small intestine and form micropores large enough to allow bacteria to pass through after digestion. Digestion-resistant intestinal beneficial bacteria described.
項ないし第３項のいずれかに記載する耐消化性腸内有用
細菌。(4) Claim 1, wherein the intestinal useful bacteria belong to the Bifidobacterium group.
Digestion-resistant intestinal useful bacteria described in any one of Items 1 to 3.
糖で被覆したことを特徴とする請求項１項ないし４項の
何れかに記載する耐消化性腸内有用細菌。(5) The digestive resistant intestinal useful bacteria according to any one of claims 1 to 4, characterized in that the edible oil and fat that coats the capsule is coated with fructooligosaccharide.
カプセルを形成し、カプセル形成と同時にまたはカプセ
ル形成後に、該カプセルに細菌が通過できる複数の孔を
穿設するか、或いは小腸内において穿設可能とし、該カ
プセル内に腸内有用細菌を収納し、しかる後該カプセル
を融点３５℃以上の食用油脂で被覆することを特徴とす
る耐消化性腸内有用細菌の製法。(6) A capsule is formed using a solution of a film-forming edible polymer compound, and at the same time or after the capsule formation, a plurality of holes are made in the capsule through which bacteria can pass, or the small intestine is 1. A method for producing digestible bacteria useful for the intestines, which comprises accommodating the bacteria useful for the intestines in the capsule, and then coating the capsule with an edible oil or fat having a melting point of 35° C. or higher.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1210102A JPH06101994B2 (en) | 1989-08-16 | 1989-08-16 | Digestion-resistant enteric useful bacteria and method for producing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1210102A JPH06101994B2 (en) | 1989-08-16 | 1989-08-16 | Digestion-resistant enteric useful bacteria and method for producing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0376561A true JPH0376561A (en) | 1991-04-02 |
| JPH06101994B2 JPH06101994B2 (en) | 1994-12-14 |
Family
ID=16583849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1210102A Expired - Fee Related JPH06101994B2 (en) | 1989-08-16 | 1989-08-16 | Digestion-resistant enteric useful bacteria and method for producing the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH06101994B2 (en) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999002042A3 (en) * | 1997-07-05 | 1999-05-27 | Nestle Sa | Frozen dessert containing lactic bacteria and fermentable fibres |
| JP2004215561A (en) * | 2003-01-14 | 2004-08-05 | Seikatsu Bunkasha:Kk | Food product for promoting fixation and proliferation of useful intestinal bacterium |
| WO2004096283A1 (en) * | 2003-05-02 | 2004-11-11 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Soft capsule film and soft capsule |
| JP2004345999A (en) * | 2003-05-21 | 2004-12-09 | Taiko Pharmaceutical Co Ltd | Bacterial cell preparation composition |
| WO2006103698A1 (en) * | 2005-03-31 | 2006-10-05 | Council Of Scientific & Industrial Research | 'edible films and coatings based on fructooligosaccharides with probiotic properties' |
| JP2010511033A (en) * | 2006-11-28 | 2010-04-08 | プロバイオティカル エス．ピー．エイ． | Compositions for bioactive ingredient administration in gynecological and rectal fields and methods of use thereof |
| US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
| US7906112B2 (en) | 2003-12-19 | 2011-03-15 | The Procter & Gamble Company | Canine probiotic Lactobacilli |
| US8168170B2 (en) | 2002-10-03 | 2012-05-01 | The Procter And Gamble Company | Compositions having an inner core and at least three surrounding layers |
| US8802179B2 (en) | 2001-04-17 | 2014-08-12 | Guy W. Miller | Non-digestible sugar-coated products and process |
| JP2014528728A (en) * | 2011-10-06 | 2014-10-30 | ネステク ソシエテ アノニム | Edible web containing microorganisms |
| US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
| US8900569B2 (en) | 2003-12-19 | 2014-12-02 | The Iams Company | Method of treating diarrhea in a canine |
| US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
| US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59220175A (en) * | 1983-05-28 | 1984-12-11 | Furointo Sangyo Kk | Coating of health food |
| JPS6110508A (en) * | 1984-06-26 | 1986-01-18 | Mitsubishi Acetate Co Ltd | Capsule and its production |
| JPS63246333A (en) * | 1987-03-31 | 1988-10-13 | Toyo Kapuseru Kk | Intestine-activating type soft capsule preparation mainly containing components resisting pantothenic acid deficiency |
-
1989
- 1989-08-16 JP JP1210102A patent/JPH06101994B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59220175A (en) * | 1983-05-28 | 1984-12-11 | Furointo Sangyo Kk | Coating of health food |
| JPS6110508A (en) * | 1984-06-26 | 1986-01-18 | Mitsubishi Acetate Co Ltd | Capsule and its production |
| JPS63246333A (en) * | 1987-03-31 | 1988-10-13 | Toyo Kapuseru Kk | Intestine-activating type soft capsule preparation mainly containing components resisting pantothenic acid deficiency |
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399124B1 (en) | 1997-07-05 | 2002-06-04 | Nestec Sa | Frozen dessert containing lactic acid bacteria |
| WO1999002042A3 (en) * | 1997-07-05 | 1999-05-27 | Nestle Sa | Frozen dessert containing lactic bacteria and fermentable fibres |
| US11033503B2 (en) | 2001-04-17 | 2021-06-15 | Guy W Miller | Non-digestible sugar-coated products and process |
| US9526743B2 (en) | 2001-04-17 | 2016-12-27 | Guy W. Miller | Non-digestible sugar-coated products and process |
| US8802179B2 (en) | 2001-04-17 | 2014-08-12 | Guy W. Miller | Non-digestible sugar-coated products and process |
| US8168170B2 (en) | 2002-10-03 | 2012-05-01 | The Procter And Gamble Company | Compositions having an inner core and at least three surrounding layers |
| JP2004215561A (en) * | 2003-01-14 | 2004-08-05 | Seikatsu Bunkasha:Kk | Food product for promoting fixation and proliferation of useful intestinal bacterium |
| WO2004096283A1 (en) * | 2003-05-02 | 2004-11-11 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Soft capsule film and soft capsule |
| JPWO2004096283A1 (en) * | 2003-05-02 | 2006-07-13 | 株式会社林原生物化学研究所 | Soft capsule film and soft capsule |
| JP2004345999A (en) * | 2003-05-21 | 2004-12-09 | Taiko Pharmaceutical Co Ltd | Bacterial cell preparation composition |
| US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
| US7906112B2 (en) | 2003-12-19 | 2011-03-15 | The Procter & Gamble Company | Canine probiotic Lactobacilli |
| US9821015B2 (en) | 2003-12-19 | 2017-11-21 | Mars, Incorporated | Methods of use of probiotic bifidobacteria for companion animals |
| US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
| US8894991B2 (en) | 2003-12-19 | 2014-11-25 | The Iams Company | Canine probiotic Lactobacilli |
| US8900569B2 (en) | 2003-12-19 | 2014-12-02 | The Iams Company | Method of treating diarrhea in a canine |
| WO2006103698A1 (en) * | 2005-03-31 | 2006-10-05 | Council Of Scientific & Industrial Research | 'edible films and coatings based on fructooligosaccharides with probiotic properties' |
| JP2010511033A (en) * | 2006-11-28 | 2010-04-08 | プロバイオティカル エス．ピー．エイ． | Compositions for bioactive ingredient administration in gynecological and rectal fields and methods of use thereof |
| US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
| US10709156B2 (en) | 2008-07-07 | 2020-07-14 | Mars, Incorporated | Pet supplement and methods of making |
| US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
| JP2014528728A (en) * | 2011-10-06 | 2014-10-30 | ネステク ソシエテ アノニム | Edible web containing microorganisms |
| US10624377B2 (en) | 2011-10-06 | 2020-04-21 | Societe Des Produits Nestle S.A. | Edible web comprising microorganisms |
| US11241030B2 (en) | 2011-10-06 | 2022-02-08 | Societe Des Produits Nestle S.A. | Edible web comprising microorganisms |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH06101994B2 (en) | 1994-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Silva et al. | Symbiotic microencapsulation to enhance Lactobacillus acidophilus survival | |
| Yao et al. | Progress in microencapsulation of probiotics: A review | |
| JPH0376561A (en) | Digestion-resistant useful enterobacterium and its preparation | |
| US6030641A (en) | Sustained release capsule and method for preparing the same | |
| JP4444496B2 (en) | Low temperature coating | |
| US7101565B2 (en) | Probiotic/prebiotic composition and delivery method | |
| JP5697598B2 (en) | Water-insoluble polymer for colon targeting: indigestible water-soluble polysaccharide-type film coating | |
| CA2825473C (en) | Protection of microbial cells from acidic degradation | |
| CN104321052B (en) | The capsule of specific disintegration in large intestine | |
| Siew et al. | The potential of organic-based amylose-ethylcellulose film coatings as oral colon-specific drug delivery systems | |
| Damodharan et al. | Co-encapsulation of lactic acid bacteria and prebiotic with alginate-fenugreek gum-locust bean gum matrix: Viability of encapsulated bacteria under simulated gastrointestinal condition and during storage time | |
| Atia et al. | A prebiotic matrix for encapsulation of probiotics: physicochemical and microbiological study | |
| RU2744452C2 (en) | Composition for targeted delivery of biologically active component into large intestine and its application | |
| WO2021073197A1 (en) | Composition containing lactic acid bacteria and use thereof | |
| JPH0441434A (en) | Lactobacillus tablet provided with enteric coating | |
| Niño-Vásquez et al. | Co-microencapsulation: a promising multi-approach technique for enhancement of functional properties | |
| Shukla et al. | Pectin-based colon-specific drug delivery | |
| CN110403198A (en) | A kind of probiotics soft capsule and preparation method thereof | |
| WO2021152869A1 (en) | Enteric composition, food/beverage item containing said enteric composition, method for controlling disintegration time for said enteric composition, and method for manufacturing said enteric composition | |
| JP2931811B2 (en) | Sustained release capsule | |
| CN107072282A (en) | Alimentation composition and its application comprising prebiotics and lactoferrin | |
| JPH0482827A (en) | Entero-soluble capsule | |
| KR20210123989A (en) | Method for producing soft capsule type functional health food | |
| KR20050105669A (en) | Probiotic composition | |
| JPH03232815A (en) | Drug capsule for enteropathy and its production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081214 Year of fee payment: 14 |
|
| LAPS | Cancellation because of no payment of annual fees |